Le Lézard
Classified in: Health
Subject: ACC

IRRAS AB publishes Interim Report for the Period January to September 2019


STOCKHOLM, Nov. 14, 2019 /PRNewswire/ -- "Since the US is the world's largest market for neurosurgical procedures, we have focused much of our team's resources toward supporting a successful early market introduction. Response to our IRRAflow technology remains strong, and our sales funnel is full. Patient treatments with IRRAflow continued to increase, and multiple hospital systems moved from evaluating IRRAflow into the approval and purchasing phase."

Kleanthis G. Xanthopoulos, Ph.D., President and CEO of IRRAS

Third quarter, July - September 2019           

Period January - September 2019           

Important events during the quarter           

Other key accomplishments           

Important events after the end of the quarter           

The report is available on the company's website: https://investors.irras.com/en/reports-presentations
 

About IRRAS

IRRAS AB is a global healthcare company focused on delivering innovative medical technologies to our customers and their patients. IRRAS designs, develops and commercializes products that improve patient outcomes and decrease the overall cost of care by addressing complications associated with current treatment methods in neurocritical care. IRRAS currently markets and sells its IRRAflow and Hummingbird product lines to hospitals worldwide through its direct sales organizations in the U.S. and select European countries and a network of distribution partners in other markets. 

IRRAS maintains its headquarters in Stockholm, Sweden, with corporate offices in Munich, Germany, and San Diego, California, USA. For more information, please visit www.irras.com.

IRRAS AB (publ) is listed on Nasdaq First North Premier Growth Market (ticker: IRRAS). Redeye AB is certified adviser of the company with email [email protected]  or phone +46 8 121 576 90.

For more information, please contact:

USA
Kleanthis G. Xanthopoulos, Ph.D.
President and CEO
[email protected]  

Europa
Sabina Berlin
CFO
+46 73 951 95 02
[email protected]

This document is considered information that IRRAS is obliged to disclose pursuant to the EU Market Abuse Regulation. The information was released for public disclosure, through the agency of the contact person above, on November 14, 2019 at 8:00 a.m. (CET).

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/irras/r/irras-ab-publishes-interim-report-for-the-period-january-to-september-2019,c2961039

The following files are available for download:

https://mb.cision.com/Main/16550/2961039/1140918.pdf

Release

 

SOURCE IRRAS


These press releases may also interest you

at 21:30
The "Whole Genome and Exome Sequencing Markets by Application, Organism and Product with Executive and Consultant Guides. Includes Direct to Consumer Analysis. 2023 to 2027" report has been added to  ResearchAndMarkets.com's offering. Will all...

at 20:50
Pharma (1167.HK), a clinical-stage oncology company drugging the undruggable targets, today announced its 2023 annual results. The revenue was RMB63.5 million, the R&D investment was RMB372 million, the cash and cash equivalent at the end of 2023 was...

at 20:35
InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company announced that the first patient in China has been dosed in the Phase 1b clinical study of the combination of InnoCare's novel SHP2 (Src Homology 2 domain containing...

at 19:30
Willow Biosciences Inc. ("Willow" or the "Company") , a leading biotechnology...

at 18:56
Nutex Health Inc. ("Nutex Health" or the "Company") (NASDAQ:...

at 18:30
Striking Teamsters at pharmaceutical giant Cencora (formerly known as AmerisourceBergen) rallied today outside the company's Sacramento distribution center. The 124 warehouse workers are members of Teamsters Local 150 and have been on strike since...



News published on and distributed by: